Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis

Clinica Chimica Acta

Volumn 455, Issue , 2016, Pages 161-171

  Mateen, Somaiya ^a   Zafar, Atif ^b   Moin, Shagufta ^a   Khan, Abdul Qayyum ^a   Zubair, Swaleha ^b  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Anti cytokine agents; Anti inflammatory cytokines; Cytokine gene polymorphism; Pro inflammatory cytokines; Rheumatoid arthritis

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 32; INTERLEUKIN 33; INTERLEUKIN 35; INTERLEUKIN 4; INTERLEUKIN 6; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL PRODUCT;

CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENETIC ASSOCIATION; HUMAN; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELL; NONHUMAN; PATHOGENESIS; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; ARTHRITIS, RHEUMATOID; B LYMPHOCYTE; IMMUNOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; T LYMPHOCYTE;

ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; BIOLOGICAL PRODUCTS; CYTOKINES; HUMANS; T-LYMPHOCYTES;

EID: 84960934172     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2016.02.010     Document Type: Review

References (92)

1. Marieke B., Jurgen V.H., Tom W.J., et al. Genetics of rheumatoid arthritis: what have we learned?. Immunogenetics 2011, 63:459-466.
2. Dhawan S.S., Quyyumi A.A. Rheumatoid arthritis and cardiovascular disease. Curr. Atheroscler. Rep. 2008, 10:128-133.
3. Marie-Christophe B., Luca S., Salima C., et al. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J. Autoimmun. 2012, 29:222-228.
4. Stockinger B., Veldhoen M. Differentiation and function of Th17 T cells. Curr. Opin. Immunol. 2007, 19:281-286.
5. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
6. Smolen J.S., Aletaha D., Koeller M., et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007, 370:1861-1874.
7. Sebastien V., Darren P., Soumya R. Genetics and epigenetics of rheumatoid arthritis. Nat. Rev. Rheumatol. 2013, 9:141-153.
8. Arvikar S.L., Collier D.S., Fisher M.C., et al. Clinical correlations with porphyromonas gingivalis antibody responses in patients with early rheumatoid arthritis. Arthritis Res. Ther. 2013, 15:R109.
9. Kerstin K., Steffen G. Epigenetics in rheumatoid arthritis. Curr. Opin. Rheumatol. 2015, 27:76-82.
10. Tibor T.G., Katalin M., Tibor A.R. Epigenetics in the pathogenesis of rheumatoid arthritis. BMC Med. 2014, 12:35.
11. Song Y.J., Li G., He J. Bioinformatics-based identification of MicroRNA-regulated and rheumatoid arthritis-associated genes. PLoS ONE 2015, 10.
12. Smolen J.S., Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat. Rev. Drug Discov. 2003, 2:473-488.
13. Rantapaa-Dahlqvist S., de Jong B.A., Berglin E., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003, 48:2741-2749.
14. Hochberg M.C., Johnston S.S., John A.K. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr. Med. Res. Opin. 2008, 24:469-480.
15. Paula F.S., Alves J.D. Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis. Biologics 2014, 8:1-12.
16. Schellekens G.A., de Jong B.A., van den Hoogen F.H., et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis specific autoantibodies. J. Clin. Invest. 1998, 101:273-281.
17. Filipe S.P., José Delgado A. Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis. Biol. Targets Ther. 2014, 8:1-12.
18. Firestein G.S. Etiology and Pathogenesis of Rheumatoid Arthritis. Kelley's Textbook of Rheumatology 2009, Saunders, Philadelphia, PA. eighth ed. G.S. Firestein, R.C. Budd, E.D.J. Harris, I.B. McInnes, S. Ruddy, J.S. Sergent (Eds.).
19. Wan Y.Y., Flavell R.A. TGF-beta and regulatory T cell in immunity and autoimmunity. J. Clin. Immunol. 2008, 28:647-659.
20. Bettelli E., Carrier Y., Gao W., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
21. Zhou L., Lopes J.E., Chong M.M., et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008, 453:236-240.
22. Vasanthi P., Nalini G., Rajasekhar G. Role of tumor necrosis factor-alpha in rheumatoid arthritis: a review. APLAR J. Rheumatol. 2007, 10:270-274.
23. Edrees A.F., Misra S.N., Abdou N.I. Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin. Exp. Rheumatol. 2005, 23:469-474.
24. Yang X.D., Tisch R., Singer S.M., et al. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. the early development of autoimmunity and the diabetogenic process. J. Exp. Med. 1994, 180:995-1004.
25. Masli S., Turpie B. Anti-inflammatory effects of tumour necrosis factor (TNF)-alpha are mediated via TNF-R2 (p75) in tolerogenic transforming growth factor-beta-treated antigen-presenting cells. Immunology 2009, 127:62-72.
26. Ignacio R.P., Mercedes F.M., Francisco J.B. Gene Polymorphisms and pharmacogenetics in rheumatoid arthritis. Curr. Genomics 2008, 9:381-393.
27. Syed S., Fayaz A.S., DILAFROZE The association between TNFα gene polymorphisms and susceptibility to rheumatoid arthritis in an ethnic Kashmiri population: relationship with disease activity and severity markers. Int. J. Rheum. Dis. 2013.
28. Kay J., Calabrese L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology 2004, 43:iii2-iii9.
29. Arend W.P. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Semin. Arthritis Rheum. 2001, 30:1-6.
30. McInnes I., Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 2007, 7:429-442.
31. Chizzolini C., Dayer J.M., Miossec P. Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance?. Arthritis Res. Ther. 2009, 11:246.
32. Lili M., Dalma V., Erzsebet K., et al. Interleukins and interleukin receptors in rheumatoid arthritis: research, diagnostics and clinical implications. World J. Orthod. 2014, 18:516-536.
33. Pia I., Juha P. Pro- and anti-inflammatory cytokines in rheumatoid arthritis. Ann. Med. 1997, 29:499-507.
34. Finnegan A., Mikecz K., Tao P., et al. Proteoglycan (aggrecan) - induced arthritis in BALB/c mice is a Th1- type disease regulated by Th2 cytokines. J. Immunol. 1999, 163:5383-5390.
35. Joosten L.A.B., Lubberts E., Durez P., et al. Role of interleukin-4 and interleukin-10 in murine collagen- induced arthritis: protective effect of interleukin- 4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum. 1997, 40:249-260.
36. Hyun K.P., Su K.K., Hae Y.K. Promoter polymorphism (-590, T/C) of interleukin 4 (IL4) gene is associated with rheumatoid arthritis; updated meta-analysis. Saudi J. Biol. Sci. 2016.
37. Stefan Rose-J IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int. J. Biol. Sci. 2012, 8:1237-1247.
38. Dayer J.M., Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology 2010, 49:15-24.
39. Yuji Y., Toshio T. Interleukin 6 and rheumatoid arthritis. Biomed. Res. Int. 2014, 2014.
40. Xiang L., Wei C., Ming N. The effects of Gene Polymorphisms in interleukin-4 and interleukin-6 on the susceptibility of rheumatoid arthritis in a Chinese population. Biomed. Res. Int. 2014, 265435.
41. Churchman S.M., Ponchel F. Interleukin-7 in rheumatoid arthritis. Rheumatology 2008, 47:753-759.
42. Hartgring S.A.Y., Bijlsma J.W.J., Lafeber F.P.J.G., et al. Interleukin-7 induced immunopathology in arthritis. Ann. Rheum. Dis. 2006, 65:iii69-iii74.
43. Chizzolini C., Parel Y., Scheja A., et al. Polarized subsets of human thelper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblasts. Arthritis Res. Ther. 2005, 8:R10.
44. Mottonen M., Isomaki P., Saario R., et al. Interleukin-10 inhibits the capacity of synovial macrophages to function as antigen-presenting cells. Br. J. Rheumatol. 1998, 37:1207-1214.
45. Joel A.G.R.O., Floris P.J.G.L., Bijlsma J.W.J. Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum. 2001, 44:3-12.
46. Apparailly F., Verwaerde C., Jacquet C., et al. Adenovirus-mediated transfer of viral IL-10 gene inhibits murine Collagen-induced arthritis. J. Immunol. 1998, 160:5213-5220.
47. Richard M.P., Shiva S. Possible roles of IL-12-family cytokines in rheumatoid arthritis. Nat. Rev. Rheumatol. 2013, 9:252-256.
48. Petrovic-Rackov L., Pejnovic N. Clinical significance of IL-18, IL-15, IL-12 and TNFα measurement in rheumatoid arthritis. Clin. Rheumatol. 2006, 25:448-452.
49. En-Yin W., Qin Y., Zhi-Gang L. Association of polymorphisms in interleukin 12 genes (IL-12 A and -B) with rheumatoid 1 arthritis in a Chinese population. Clin. Exp. Immunol. 2015, 180:83-89.
50. Shen L., Zhang H., Zhou X., et al. Association between polymorphisms of interleukin 12 and rheumatoid arthritis associated biomarkers in a Chinese population. Cytokine 2015, 76:363-367.
51. De Waal M.R., Figdor C.G., Huijbens R., et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. J. Immunol. 1993, 151:6370-6381.
52. Steven M.O., Vera A.D. Anti-inflammatory cytokines. Chest 2000, 117:1162-1172.
53. Goldbergova M.P., Nemec P., Lipkova J., et al. Relation of IL-6, IL-13 and IL-15 gene polymorphisms to the rheumatoid factors, anti-CCP and other measures of rheumatoid arthritis activity. Int. J. Immunogenet. 2014, 41:34-40.
54. Gholamreza A., Farhad J.N., Abbas M. Th17 Cells in Immunopathogenesis and treatment of rheumatoid arthritis. Int. J. Rheum. Dis. 2013, 16:243-253. (831).
55. Agarwal S., Misra R., Aggarwal A. Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J. Rheumatol. 2008, 35:515-519.
56. Adamopoulos I.E., Chao C.C., Geissler R., et al. Interleukin-17 A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res. Ther. 2010, 12:R29. (2010).
57. Kim K.W., Cho M.L., Kim H.R., et al. Up-regulation of stromal cell-derived factor 1 (CXCL12) production in rheumatoid synovial fibroblasts through interactions with T lymphocytes: role of interleukin-17 and CD40L- CD40 interaction. Arthritis Rheum. 2007, 56:1076-1086.
58. Honorati M.C., Neri S., Cattini L., et al. Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthr. Cartil. 2006, 14:345-352.
59. Sarah L.G. Role of IL-17 in the pathogenesis of rheumatoid arthritis. Curr. Rheumatol. Rep. 2009, 11:365-370.
60. Koenders M.I., Lubberts E., Oppers-Walgreen B., et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am. J. Pathol. 2005, 167:141-149.
61. Sarkar S., Cooney L.A., White P., et al. Regulation of pathogenic IL-17 responses in Collagen- induced arthritis: roles of endogenous interferon-gamma and IL-4. Arthritis Res. Ther. 2009, 11:R158.
62. Katarzyna Bogunia-K Jerzy S, Anna M et al. IL-17 A, IL-17F and IL-23R Gene Polymorphisms in polish patients with rheumatoid arthritis. Arch. Immunol. Ther. Exp. 2015, 63:215-221.
63. Marie C.B., Luca S., Salima C. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J. Autoimmun. 2012, 39. (222e228).
64. Brian A., Erin H., Kamal D.M. A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis. J. Interf. Cytokine Res. 2011, 31:927-940.
65. Banda N.K., Vondracek A., Kraus D., et al. Mechanisms of inhibition of Collagen induced arthritis by murine IL-18 binding protein. J. Immunol. 2003, 170:2100-2105.
66. Ettinger R., Kuchen S., Lipsky P.E. The role of IL-21 in regulating B-cell function in health and disease. Immunol. Rev. 2008, 223:60-86.
67. Zhou L., Ivanov I.I., Spolski R., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential 815 engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 2007, 8:967-974.
68. Niu X., He D., Zhang X., et al. IL-21 regulates Th17 cells in rheumatoid arthritis. Hum. Immunol. 2010, 71:334-341.
69. Young D.A., Hegen M., Ma H.L., et al. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum. 2007, 56:1152-1163.
70. Daha N.A., Kurreeman F.A., Marques R.B. Confirmation of STAT4, IL2/IL21, and CTLA4 polymorphisms in rheumatoid arthritis. Arthritis Rheum. 2009, 60:1255-1260.
71. Chen L., Wei X.Q., Evans B., et al. IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-κB (RANK) expression in myeloid precursor cells. Eur. J. Immunol. 2008, 38:2845-2854.
72. Li X., Kim K.W., Cho M.L., et al. IL-23 induces receptor activator of NF-κB ligand expression in fibroblast- like synoviocytes via STAT3 and NF-κB signal pathways. Immunol. Lett. 2010, 127:100-107.
73. Lemos H.P., Grespan R., Vieira S.M., et al. Prostaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFNgamma production. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:5954-5959.
74. Pflanz S., Timans J.C., Cheung J., et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4 (+) T cells. Immunity 2002, 16:779-790.
75. Cao Y., Doodes P.D., Glant T.T., et al. IL-27 induces a Th1 immune response and susceptibility to experimental arthritis. J. Immunol. 2008, 180:922-930.
76. Awasthi A., Carrier Y., Peron J.P., et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol. 2007, 8:1380-1389.
77. Kalliolias GD, Zhao B, Triantafyllopoulou A, et al. Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis Rheum. 62, 402-413.
78. Paradowska-Gorycka A., Raszkiewicz B., Jurkowska M. Association of single nucleotide polymorphisms in the IL27 gene with rheumatoid arthritis. Scand. J. Immunol. 2014, 80:298-305.
79. Joosten L.A., Netea M.G., Kim S.H., et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:3298-3303.
80. Shoda H., Fujio K., Yamaguchi Y., et al. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res. Ther. 2006, 8:R166.
81. Kim Y.G., Lee C.K., Oh J.S., et al. Effect of interleukin-32gamma on differentiation of osteoclasts from CD14+ monocytes. Arthritis Rheum. 2010, 62:515-523.
82. Schmitz J., Owyang A., Oldham E., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
83. Yuan F.L., Li X., Lu W.G., et al. IL-33: a promising therapeutic target for rheumatoid arthritis?. Expert Opin. Ther. Targets 2011, 15:529-534.
84. Xu D., Jiang H.R., Kewin P., et al. IL-33 exacerbates antigen induced arthritis by activating mast cells. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10913-10918.
85. Kunisch E., Chakilam S., Gandesiri M., et al. IL-33 regulates TNF-alpha dependent effects in synovial fibroblasts. Int. J. Mol. Med. 2012, 29:530-540.
86. Chun L., Rong M., Jianping G. Genetic variant in IL33 is associated with susceptibility to rheumatoid arthritis. Arthritis Res. Ther. 2014, 16:R105.
87. Collison L.W., Workman C.J., Kuo T.T., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-569.
88. Bardel E., Larousserie F., Charlot-Rabiega P., et al. Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J. Immunol. 2008, 181:6898-6905.
89. Niedbala W., Wei X.Q., Cai B., et al. IL-35 is a novel cytokine with therapeutic effects against Collagen-induced arthritis through the expansion of regulatory T cells and suppression of TH17 cells. Eur. J. Immunol. 2007, 37:3021-3029.
90. Kochetkova I., Golden S., Holderness K., et al. IL-35 stimulation of CD39+ regulatory T cells confers protection against Collagen II-induced arthritis via the production of IL-10. J. Immunol. 2010, 184:7144-7153.
91. Nancy V., Ronald F.V.V. Advances in the treatment of rheumatoid arthritis. Prime Rep. 2014, 6:31. (F1000).
92. Cosimo D.B. Are mesenchymal stem cells in rheumatoid arthritis the good or bad guys?. Arthritis Res. Ther. 2015, 17:113.